Pfizer (PFE) Ruling on Teva's (TEVA) Generic Celebrex Stands, Court Says -Bloomberg
More News related to PFE
- Former Pfizer Global R&D President John LaMattina Joins PureTech Ventures as Senior Partner; PureTech Announces Partner Promotions
- Monsanto (MON) Agrees to Acquire Pfizer's (PFE) Chesterfield Village Research Center for $435M
- Monsanto to Purchase Chesterfield Village Research Center From Pfizer
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX(R) (Varenicline) Compared With Placebo
More News related to TEVA
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
- Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE(R)-Related Patents
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
More News related to Corporate News
- Hovnanian Enterprises (HOV) Sees Tax Refund of $250-$275M
- Windstream (WIN) Closes Acquisition of D&E Communications, Deal Valued at $333M
- Northrop Grumman (NOC) Receives $58M Delivery Order for C-RAM Systems Integration
- Kenexa (KNXA) Opens New Office in Buenos Aires, Argentina
- Mad Catz Interactive (MCZ) Opens Office in Barcelona, Spain
Bloomberg is reporting that an appeals court said that Pfizer's (NYSE: PFE) ruling on Teva Pharmaceuticals' (Nasdaq: TEVA) generic Celebrex stands.
Related Categories
Corporate NewsStocks Mentioned
+0.17
-0.24Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
